1. Home
  2. STRA vs ZYME Comparison

STRA vs ZYME Comparison

Compare STRA & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

STRA

Strategic Education Inc.

HOLD

Current Price

$79.40

Market Cap

1.8B

Sector

Real Estate

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$24.96

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STRA
ZYME
Founded
2017
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.9B
IPO Year
1996
2022

Fundamental Metrics

Financial Performance
Metric
STRA
ZYME
Price
$79.40
$24.96
Analyst Decision
Buy
Strong Buy
Analyst Count
3
11
Target Price
$87.00
$38.90
AVG Volume (30 Days)
285.9K
556.7K
Earning Date
04-23-2026
05-07-2026
Dividend Yield
3.04%
N/A
EPS Growth
15.85
33.33
EPS
1.48
N/A
Revenue
$997,137,000.00
$105,965,000.00
Revenue This Year
$4.71
$183.10
Revenue Next Year
$4.67
N/A
P/E Ratio
$54.13
N/A
Revenue Growth
57.23
38.87
52 Week Low
$69.70
$11.02
52 Week High
$92.98
$29.75

Technical Indicators

Market Signals
Indicator
STRA
ZYME
Relative Strength Index (RSI) 51.10 45.50
Support Level $78.41 $24.79
Resistance Level $84.97 $27.54
Average True Range (ATR) 2.13 1.21
MACD 0.32 -0.22
Stochastic Oscillator 59.72 33.92

Price Performance

Historical Comparison
STRA
ZYME

About STRA Strategic Education Inc.

Strategic Education Inc. is an education services company that provides access to high-quality education through campus-based and online post-secondary education offerings, as well as through programs to develop job-ready skills for high-demand markets. The company operates through wholly-owned subsidiaries Strayer University and Capella University, both accredited post-secondary institutions of higher education located in the United States, as well as Torrens University, an accredited post-secondary institution of higher education located in Australia. It provide employees with access to affordable and industry relevant training, certificate, and degree programs. The reportable segments of the company are U.S. Higher Education, Australia/New Zealand and Education Technology Services.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: